newsfilter
← Latest News
Business Wire·

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

– Progress in addressing the FDA's recommendations regarding bioassay and dose escalations to clear the current clinical hold on the company's Investigational New Drug Application to initiate MGTA-117 Phase 1/2 clinical trial – – Enrollment c